Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denardo

Showing results (211-220 of 274) with videos related to

Pageof 28
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1976
Diagnosis of cirrhosis and hepatitis by quantitative hepatic and other reticuloendothelial clearance ratesS J DeNardo, G B Bell, G L DeNardo, et al.
Clinical Nuclear Medicine|December 1, 1985
Correlation of bioscintigraphy, contrast venography, and iodine-125 fibrinogen uptake testG L DeNardo, S J DeNardo, R F Carretta, et al.
Cancer|March 6, 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo, Jeffery Schlom, Donald J Buchsbaum, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 7, 2010
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imagingGerald L DeNardo, Arutselvan Natarajan, Saphon Hok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetrySui Shen, Sally J DeNardo, Carol M Richman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2000
Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphomaG L DeNardo, R T O'Donnell, S Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 6, 2008
Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cellsJoerg Lehmann, Arutselvan Natarajan, Gerald L Denardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji)G L DeNardo, D L Kukis, S Shen, et al.
Hybridoma|June 17, 1998
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumorX Feng, R H Pak, L A Kroger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeuticsS J DeNardo, G L DeNardo, D G DeNardo, et al.
Pageof 28

Showing results (211-220 of 274) with videos related to

Sort By:
Pageof 28
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1976
Diagnosis of cirrhosis and hepatitis by quantitative hepatic and other reticuloendothelial clearance ratesS J DeNardo, G B Bell, G L DeNardo, et al.
Clinical Nuclear Medicine|December 1, 1985
Correlation of bioscintigraphy, contrast venography, and iodine-125 fibrinogen uptake testG L DeNardo, S J DeNardo, R F Carretta, et al.
Cancer|March 6, 2002
Rationales, evidence, and design considerations for fractionated radioimmunotherapyGerald L DeNardo, Jeffery Schlom, Donald J Buchsbaum, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 7, 2010
Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imagingGerald L DeNardo, Arutselvan Natarajan, Saphon Hok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetrySui Shen, Sally J DeNardo, Carol M Richman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 16, 2000
Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphomaG L DeNardo, R T O'Donnell, S Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 6, 2008
Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cellsJoerg Lehmann, Arutselvan Natarajan, Gerald L Denardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji)G L DeNardo, D L Kukis, S Shen, et al.
Hybridoma|June 17, 1998
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumorX Feng, R H Pak, L A Kroger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeuticsS J DeNardo, G L DeNardo, D G DeNardo, et al.
Pageof 28